Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by National Cancer Institute (NCI).
Recruitment status was  Recruiting
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00470249
First received: May 3, 2007
Last updated: August 1, 2009
Last verified: July 2009
  Purpose

RATIONALE: Drugs used in chemotherapy, such as carboplatin and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving carboplatin together with gemcitabine works in treating patients with locally advanced or metastatic breast cancer.


Condition Intervention Phase
Breast Cancer
Drug: carboplatin
Drug: gemcitabine hydrochloride
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Carboplatin in Combination With Gemcitabine as a Dose Dense Schedule in Patients With Locally Advanced or Metastatic Breast Cancer That Are Resistant to Anthracyclines & Taxanes

Resource links provided by NLM:


Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Overall response rate (complete or partial response) [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Overall toxicity as assessed by NCI CTCAE v3.0 [ Designated as safety issue: Yes ]
  • Overall survival [ Designated as safety issue: No ]
  • Time to disease progression [ Designated as safety issue: No ]
  • Duration of response [ Designated as safety issue: No ]
  • Time to treatment failure [ Designated as safety issue: No ]

Estimated Enrollment: 35
Study Start Date: February 2007
Estimated Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Determine the overall response rate in patients with anthracycline- and taxane-resistant locally advanced or metastatic breast cancer treated with dose-dense carboplatin and gemcitabine hydrochloride.

Secondary

  • Determine the overall toxicity of this regimen in these patients.
  • Determine the overall survival of patients treated with this regimen.
  • Determine the time to disease progression in patients treated with this regimen.
  • Determine the duration of response in patients treated with this regimen.
  • Determine the time to treatment failure in patients treated with this regimen.

OUTLINE: This is a nonrandomized, open-label study.

Patients receive carboplatin IV over 30 minutes on day 1 and gemcitabine hydrochloride IV over 150 minutes on day 2. Treatment repeats every 14 days for up to 9 courses in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed periodically for 2 years.

PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically confirmed breast cancer

    • Locally advanced or metastatic disease
  • Recurrent or refractory disease

    • Histological or cytological confirmation required for recurrence in a solitary site
    • Must have received prior anthracycline and taxane as neoadjuvant, adjuvant, or metastatic therapy
  • Measurable disease*

    • At least 1 measurable site of disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan

      • Palpable disease allowed NOTE: *Lesions that have been irradiated in the advanced setting cannot be included as sites of measurable disease
  • No nonmeasurable disease only, including the following:

    • Bone lesions
    • Leptomeningeal disease
    • Ascites
    • Pleural or pericardial effusion
    • Inflammatory breast disease
    • Lymphangitic pulmonary disease
    • Abdominal masses that are not confirmed and followed by imaging techniques
    • Cystic lesions
  • No HER2-positive disease, defined as 3+ by IHC OR positive by FISH or chromogenic in situ hybridization
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Male or female
  • Menopausal status not specified
  • ECOG performance status 0-1
  • Estimated life expectancy ≥ 12 weeks
  • Not pregnant or nursing
  • Fertile patients must use effective contraception during and for 3 months after completion of study therapy
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Hemoglobin ≥ 9 g/dL
  • ALT or AST < 2.5 times upper limit of normal (ULN)
  • Bilirubin normal
  • Alkaline phosphatase ≤ 2.5 times ULN
  • Creatinine ≤ 1.25 times ULN OR creatinine clearance > 40 mL/min
  • Calcium ≤ 1.2 times ULN
  • No concurrent serious medical or psychiatric illness, including any serious active infection incompatible with the study
  • No other primary malignancy except carcinoma in situ of the cervix, adequately treated nonmelanomatous skin cancer, or any other malignancy previously treated ≥ 5 years ago with no evidence of recurrence
  • No peripheral neuropathy ≥ grade 2

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • Recovered from prior chemotherapy
  • Prior hormonal therapy or immunotherapy allowed

    • Antitumoral hormonal therapy must be discontinued prior to study entry
  • More than 4 weeks since prior radiotherapy and recovered
  • No prior radiotherapy to the whole pelvis or to ≥ 25% of the bone marrow
  • No prior gemcitabine hydrochloride, cisplatin, or carboplatin
  • No other cytotoxic chemotherapy for 21 days before and for 14 days after completion of study therapy
  • More than 30 days since prior treatment with a drug (not including study drug) that has not received regulatory approval for any indication at the time of study entry
  • Bisphosphonate therapy may not be initiated or discontinued within 4 weeks of study entry
  • No more than 1 prior course of chemotherapy for metastatic disease

    • Prior chemotherapy in the adjuvant setting allowed
  • Concurrent palliative radiotherapy to existing painful lesions (soft tissue or bone) allowed

    • New bone pain requiring radiotherapy > 4 weeks after first study treatment considered disease progression
    • New pain in a soft tissue lesion without other objective changes may be irradiated provided ≥ 1 other site of nonirradiated measurable disease exists
  • No other concurrent anticancer treatment
  • No concurrent tamoxifen citrate, aromatase inhibitors, or progestagens
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00470249

Locations
United Kingdom
Royal Bournemouth Hospital NHS Trust Recruiting
Bournemouth, England, United Kingdom, BH7 7DW
Contact: Tamas Hickish, MD    44-1202-704-789    tamas.hickish@rbch.nhs.uk   
Portsmouth Oncology Centre at Saint Mary's Hospital Recruiting
Portsmouth Hants, England, United Kingdom, PO3 6AD
Contact: Caroline Archer, MD    44-23-9228-6000 ext. 2363      
Southampton General Hospital Recruiting
Southampton, England, United Kingdom, SO16 6YD
Contact: Nicholas Murray, MD    44-238-079-5165      
Sponsors and Collaborators
University Hospital Southampton NHS Foundation Trust.
Investigators
Study Chair: Nicholas Murray, MD University Hospital Southampton NHS Foundation Trust.
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00470249     History of Changes
Other Study ID Numbers: CDR0000542627, USCTU-BR2056-GemCarbo, LILLY-USCTU-BR2056-GemCarbo, EUDRACT-2005-005164-83, EU-20728, USCTU-CAN-0438
Study First Received: May 3, 2007
Last Updated: August 1, 2009
Health Authority: Unspecified

Keywords provided by National Cancer Institute (NCI):
stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer
recurrent breast cancer
male breast cancer
stage IIIA breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Gemcitabine
Carboplatin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Radiation-Sensitizing Agents

ClinicalTrials.gov processed this record on September 16, 2014